Table 1.
Characteristics of the EORTC-26101 clinical study and biomarker cohort.
| EORTC-26101 study cohort | EORTC-26101 biomarker cohort | P value | |
|---|---|---|---|
| N (%) | 596 (100) | 380 (63.8) | |
| Sex | |||
| Female | 223 (37.4) | 153 (40.3) | 0.38 |
| Male | 373 (62.6) | 227 (59.7) | |
| OS [median (95% CI)] | 8.9 (8.3–9.6) | 9.2 (8.4–10.0) | 0.57 |
| PFS [median (95% CI)] | 2.9 (2.8–3.0) | 2.9 (2.8–3.4) | 0.48 |
| Age [mean ± SD] | 56.8 ± 10.7 | 57.0 ± 10.7 | 0.76 |
| Steroid use | |||
| yes | 295 (49.5) | 181 (47.6) | 0.60 |
| no | 301 (50.5) | 199 (52.4) | |
| ECOG performance status | |||
| 0 | 204 (34.2) | 139 (36.6) | 0.49 |
| >0 | 392 (65.8) | 241 (63.4) | |
| Tumor diameter | |||
| Equal or smaller than 40 mm | 323 (54.2) | 210 (55.3) | 0.79 |
| Larger than 40 mm | 273 (45.8) | 170 (44.7) | |
| Origin of tissue for molecular analysis | |||
| Primary tumor | NA* | 245 (64.5) | NA* |
| Progressive tumor | 2 (0.5) | ||
| No information available | 133 (35.0) | ||
| Treatment | |||
| Lomustine | 149 (25.0) | 99 (26.1) | 0.87 |
| Lomustine + bevacizumab | 288 (48.3) | 189 (49.7) | |
| Sequence | 159 (26.7) | 92 (24.2) | |
| MGMT | |||
| Methylated | NA* | 167 (43.9) | NA* |
| Unmethylated | 146 (38.4) | ||
| Not determinable | 67 (17.6) | ||
| IDH | |||
| Wild-type | NA* | 370 (97.4) | NA* |
| Mutated | 10 (2.6) | ||
Clinical characteristics did not differ significantly between the clinical study and biomarker cohort. *NA, not available; inherent discrepancy between the whole cohort, which contains patients with and without biomarker data available, and the biomarker cohort.
Abbreviation: ECOG, Eastern Cooperative Oncology Group.